{"id":"NCT00090233","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Rotavirus Efficacy and Safety Trial (REST)(V260-006)","officialTitle":"Safety and Efficacy of Pentavalent (G1, G2, G3, G4 , and P1) Human-Bovine Reassortant Rotavirus Vaccine in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-01","primaryCompletion":"2004-10","completion":"2004-10","firstPosted":"2004-08-27","resultsPosted":"2011-05-05","lastUpdate":"2015-10-05"},"enrollment":69274,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Rotavirus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Rotateq™","otherNames":["V260"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to evaluate the safety of the investigational rotavirus vaccine and the efficacy to prevent rotavirus gastroenteritis.","primaryOutcome":{"measure":"Intussusception Within 42 Days Following Any Dose of RotaTeq™/Placebo","timeFrame":"Within 42 days following any dose of RotaTeq™/placebo","effectByArm":[{"arm":"RotaTeq™","deltaMin":6,"sd":null},{"arm":"Placebo","deltaMin":5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["16394299","20540778"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":863,"n":34904},"commonTop":["Pyrexia","Upper respiratory tract infection","Diarrhoea","Irritability","Vomiting"]}}